Results 51 to 60 of about 5,671 (151)

Healthy Participant Versus Patient Selection for Clinical Pharmacology Studies in Small‐Molecule Oncology Drug Development

open access: yes
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta   +3 more
wiley   +1 more source

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study

open access: yesThe Prostate, Volume 86, Issue 11, Page 1233-1240, August 2026.
ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma   +18 more
wiley   +1 more source

To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone

open access: yesTherapeutic Advances in Urology, 2019
The recently published phase II prospective SWITCH trial evaluated whether patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate could benefit from a ‘steroid switch’ from prednisone to dexamethasone.
Elisa Zanardi   +4 more
doaj   +1 more source

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

open access: yesTrials, 2017
Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking.
Carsten-Henning Ohlmann   +6 more
doaj   +1 more source

Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis

open access: yesAdvanced Science, Volume 13, Issue 37, 3 July 2026.
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu   +18 more
wiley   +1 more source

Neuroendocrine Transformation Without PSA Elevation in High‐Risk Metastatic Castration‐Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration‐sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate‐specific antigen.
Yoshihiro Nakagami   +9 more
wiley   +1 more source

Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer With PSA‐Discordant Progression: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction The combination of enzalutamide and radium‐223 has demonstrated clinical efficacy in metastatic castration‐resistant prostate cancer; however, real‐world evidence remains limited, particularly with PSA–discordant progression. Case Presentation A 74‐year‐old man with high‐risk localized prostate cancer was treated with androgen ...
Yamato Numata   +9 more
wiley   +1 more source

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer

open access: yesTranslational Oncology, 2016
BACKGROUND: Abiraterone acetate is an effective drug for castration-resistant prostate cancer, but cardiac serious adverse events (SAEs) may occur. We studied their association with N-terminal pro–brain natriuretic peptide (NT-proBNP) and troponin T (TnT)
Sara Campora   +19 more
doaj   +1 more source

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature

open access: yesClinical Case Reports, 2019
Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival.
Oliver E. Yausep   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy